Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY APPOINTS DISTINGUISHED UCLA ONCOLOGY SURGEON TO SAB, ENHANCING BOARD'S EXPERTISE IN SURGICAL ONCOLOGY AND TRANSLATIONAL ONCOLOGY RESEARCH AIMED AT IMPROVING MULTIDISCIPLINARY TREATMENT STRATEGIES COMPANY APPOINTS DISTINGUISHED UCLA ONCOLOGY SURGEON TO SAB, ENHANCING BOARD'S EXPERTISE IN SURGICAL ONCOLOGY AND TRANSLATIONAL ONCOLOGY RESEARCH AIMED AT IMPROVING MULTIDISCIPLINARY TREATMENT STRATEGIES

RENOVORX STRENGTHENS SCIENTIFIC ADVISORY BOARD (SAB) WITH PANCREATIC CANCER EXPERT TIMOTHY DONAHUE, MD

MOUNTAIN VIEW, CALIF., NOV. 04, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC . (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE-SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH  , A PATENTED, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT SHAUN BAGAI, CHIEF EXECUTIVE OFFICER, WILL BE PARTICIPATING AT THE CANACCORD GENUITY MEDTECH, DIAGNOSTICS & DIGITAL HEALTH & SERVICES FORUM, TO BE HELD ON NOVEMBER 20, 2025.

RENOVORX CEO SHAUN BAGAI TO PARTICIPATE AT THE CANACCORD GENUITY MEDTECH, DIAGNOSTICS & DIGITAL HEALTH & SERVICES FORUM ON NOVEMBER 20TH

MOUNTAIN VIEW, CALIF., OCT. 27, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH  , A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT IT WILL HOST ITS THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON NOVEMBER 13, 2025, AT 4:30 P.M.

RENOVORX TO HOST THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON NOVEMBER 13TH AT 4:30 P.M. ET

LOS ALTOS, CALIF., OCT. 09, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC.

RENOVORX EXPANDS SCIENTIFIC ADVISORY BOARD WITH INTERNATIONALLY RENOWNED INTERVENTIONAL ONCOLOGIST, THIERRY DE BARE, MD, PHD

FIRST REGISTRY-ELIGIBLE PATIENT PROCEDURE COMMENCED AT THE UNIVERSITY OF VERMONT CANCER CENTER BAPTIST HEALTH MIAMI CANCER INSTITUTE AND UNIVERSITY OF PITTSBURGH MEDICAL CENTER JOIN THE UNIVERSITY OF VERMONT CANCER CENTER AS PARTICIPATING CLINICAL SITES THE PANTHER STUDY IS GATHERING EXPANDED SAFETY AND PERFORMANCE DATA OF THE FDA-CLEARED RENOVOCATH  DEVICE AND ITS ASSOCIATED SURVIVAL OUTCOMES IN PATIENTS DIAGNOSED WITH SOLID TUMORS MOUNTAIN VIEW, CALIF., SEPT. 25, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC.

RENOVORX'S PANTHER POST-MARKETING REGISTRY STUDY PROGRESSES WITH FIRST CLINICAL PROCEDURE AND ADDITION OF TWO PARTICIPATING CLINICAL SITES

MOUNTAIN VIEW, CALIF., SEPT. 11, 2025 (GLOBE NEWSWIRE) -- RENOVORX, INC . (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH  , A PATENTED, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT SHAUN BAGAI, CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE IACCESS ALPHA VIRTUAL BEST IDEAS FALL INVESTMENT CONFERENCE 2025, HELD ON SEPTEMBER 16-17, 2025.

RENOVORX CEO SHAUN BAGAI TO PRESENT AT IACCESS ALPHA VIRTUAL BEST IDEAS FALL INVESTMENT CONFERENCE 2025 ON SEPTEMBER 16TH

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A PATENTED, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT SHAUN BAGAI, CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE. THE CONFERENCE WILL BE HELD AT THE LOTTE NEW YORK PALACE HOTEL IN NEW YORK CITY, SEPTEMBER 8-10, 2025. MR. B.

RENOVORX CEO SHAUN BAGAI TO PRESENT AT H.C. WAINWRIGHT'S 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE IN NEW YORK CITY, SEPTEMBER 8-10, 2025

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED ITS FINANCIAL RESULTS AND BUSINESS UPDATE TO SHAREHOLDERS FOR THE SECOND QUARTER ENDED JUNE 30, 2025. WE ARE PLEASED TO REPORT SECOND QUARTER 2025 REVENUE OF OVER $400,000. THIS GROWTH HIGHLIGHTS THE STRONG CLINICAL NEED AND MARKET.

RENOVORX REPORTS COMMERCIAL REVENUE GROWTH IN THE SECOND QUARTER 2025 AND ANNOUNCES POSITIVE INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDATION TO CONTINUE PIVOTAL PHASE III TIGER-PAC TRIAL BASED ON INTERIM DATA REVIEW

RENOVORX INCREASES ITS COMMERCIAL FOOTPRINT TO THIRTEEN LEADING NATIONAL CANCER INSTITUTE-DESIGNATED AND COMMUNITY CENTERS APPROVED TO PURCHASE RENOVOCATH

RENOVORX EXPANDS U.S. COMMERCIALIZATION EFFORTS FOR THE RENOVOCATH DEVICE WITH GROWING CUSTOMER DEMAND AND KEY LEADERSHIP HIRE

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A PATENTED, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THE LAUNCH OF THE PANTHER POST-MARKETING REGISTRY STUDY (NCT06805461). THE INITIATION OF THIS STUDY DEMONSTRATES RENOVORX'S COMMITMENT TO INNOVATION AND RENOVOCATH'S CURRENT AND FUTURE POTENTIAL. THE STUDY WILL SERVE AS A CRITICAL.

RENOVORX LAUNCHES MULTI-CENTER POST-MARKETING REGISTRY STUDY TO EVALUATE CANCER TREATMENT DELIVERED BY RENOVOCATH DEVICE TO SOLID TUMORS

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED IT WILL HOST ITS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON AUGUST 14, 2025, AT 4:30 P.M. ET. ADDITIONAL DETAILS WILL BE AVAILABLE IN THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT H.

RENOVORX TO HOST SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON AUGUST 14TH AT 4:30 P.M. ET

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED ITS FINANCIAL RESULTS AND BUSINESS UPDATES FOR THE FIRST QUARTER ENDED MARCH 31, 2025. RENOVOCATH POWERS RENOVORX'S PATENTED TRANS-ARTERIAL MICRO-PERFUSION (TAMP) THERAPY PLATFORM. I AM PLEASED TO REPORT A MILESTONE EVENT FOR RENO.

RenovoRx, Inc.

RNXT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RenovoRx, Inc.

RNXT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RNXT